title: The yin yang of sunitinib: One drug, two doses, and multiple outcomes.
abstract: Our recent work showed that sunitinib exerts dual effect on cancer cells in different dose ranges. In clinically relevant doses, cancer cells tolerate sunitinb cytotoxicity by upregulating pro-survival MCL-1 and activating mTORC1 signaling. Inhibition of MCL-1 or mTORC1 sensitized cancer cells to sunitinib. Analysis of tissues from patients correlated MCL-1/mTORC1 induction with resistance to sunitinib.
authors.affiliation: Department of Microbiology and Immunobiology, Max F. Perutz Laboratories, University of Vienna , Vienna, Austria.
authors.forename: Mohamed
authors.initials: M
authors.lastname: Elgendy
keywords: Autophagy; MCL-1; Sunitinib; cell death; mTOR; mTORC1